Delisting of Securities of Tuscan Holdings Corp. II; Clovis Oncology, Inc.; ZyVersa Therapeutics, Inc.; Otonomy, Inc., and Forward Pharma A/S from The Nasdaq Stock Market

Rhea-AI Summary

The Nasdaq Stock Market announced the delisting of several companies, including Tuscan Holdings Corp. II, Clovis Oncology, Inc., ZyVersa Therapeutics, Inc., Otonomy, Inc., and Forward Pharma A/S. Securities for these companies have been suspended since late 2022 and have not traded on Nasdaq. Nasdaq will file a Form 25 with the Securities and Exchange Commission to finalize the delistings, which are effective ten days post-filing. For additional details, companies' public filings should be reviewed.

Positive

• None.

Negative

• Delisting of Tuscan Holdings Corp. II due to suspension since November 21, 2022.
• Delisting of Clovis Oncology, Inc. due to suspension since December 21, 2022.
• Delisting of ZyVersa Therapeutics, Inc. warrants due to suspension since December 21, 2022.
• Delisting of Otonomy, Inc. due to suspension since December 23, 2022.
• Delisting of Forward Pharma A/S due to suspension since December 28, 2022.

NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, unit, and warrant of Tuscan Holdings Corp. II. Tuscan Holdings Corp. II’s securities were suspended on November 21, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Clovis Oncology, Inc. Clovis Oncology, Inc.’s securities were suspended on December 21, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the warrants of ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc.’s warrants were suspended on December 21, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Otonomy, Inc. Otonomy, Inc.’s securities were suspended on December 23, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the American Depositary Shares of Forward Pharma A/S. Forward Pharma A/S’s securities were suspended on December 28, 2022, and have not traded on Nasdaq since that time.

Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delistings. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delisting and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.

-NDAQO-

FAQ

Why were Tuscan Holdings Corp. II's stocks delisted from Nasdaq?

Tuscan Holdings Corp. II was delisted due to suspension of its securities since November 21, 2022.

What led to the delisting of Clovis Oncology, Inc. from Nasdaq?

Clovis Oncology, Inc. was delisted after its securities were suspended on December 21, 2022.

When were ZyVersa Therapeutics, Inc. warrants suspended and delisted?

The warrants of ZyVersa Therapeutics, Inc. were suspended and subsequently delisted after December 21, 2022.

What is the status of Otonomy, Inc. on the Nasdaq?

Otonomy, Inc. was suspended on December 23, 2022, and is being delisted from Nasdaq.

Why was Forward Pharma A/S delisted from Nasdaq?

Forward Pharma A/S's securities were suspended on December 28, 2022, leading to its delisting.